This Cytokinetics Director Sold 5,000 Shares in November. Is It Time to Dump the Biopharmaceutical Stock?
It targets healthcare providers and patients affected by heart failure, neuromuscular, and rare muscle diseases, with a focus on the U.S. and global biopharmaceutical markets.How does the transaction value relate to Cytokinetics, Incorporated's one-year stock performance? The ~64.73, following a 27.36% total return for the stock over the preceding 12 months as of the transaction date.What is the current value of the insider's remaining direct position? Based on ...